EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gaps and paths forward in cancer pharmacology and translational research

Elizabeth A Hughes, Lindsay L Davenport, Christopher Zdyrski, Aleksandra Pawlak, Jonathan P Mochel, Eugene F Douglass

Frontiers in Pharmacology · 10.04.2026 · 17

DOI: 10.3389/fphar.2026.1779049 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.04.2026. Verfasst von Elizabeth A Hughes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical and Biomedical Science, College of Pharmacy, UGA, Athens, GA, United States. Die Arbeit nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As drug development costs continue to rise, there is a need to reframe how drug efficacy is evaluated in preclinical models to reduce the rate of false positives. The “valley of death” refers to the gap between bench research and clinical translation. In particular, oncology chemotherapies have the highest rate of drug failure compared to other drug classes. While there has been progress in overall cancer survival, some cancers and patient populations still have a poor prognosis. To bridge the gaps of drug failure and aid underserved patient populations, drug translation cannot be viewed as a purely linear process, but one in which continual refinement is used to create more efficacious drug candidates. Additionally, pharmacokinetic-pharmacodynamic modeling could prove instrumental in better understanding drug efficacy in cellular models and in evaluating clinical translation potential with greater accuracy. The path forward in clinical pharmacology is to view drug development and efficacy as a dynamic process rather than a purely linear fashion. This review discusses traditional pharmacodynamic and pharmacokinetic evaluation methods, as well as pharmacokinetic-pharmacodynamic models of tumor growth inhibition.

Schlagwörter

Stichwörter der Autor:innen

PK-PD (pharamacokinetic-pharmacodynamic) modelcancer drug discovery and developmentdrug efficacytranslational gaptranslational medicine

Autor:innen und Institutionen

  • Pharmaceutical and Biomedical Science, College of Pharmacy, UGA, Athens, GA, United States.
  • Precision One Health Initiative, Department of Pathology, College of Veterinary Medicine, Athens, GA, United States.
  • Precision One Health Initiative, Department of Physiology and Pharmacology, College of Veterinary Medicine, Athens, GA, United States.
  • Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland.

Zitieren

APA

Hughes, E. A., Davenport, L. L., Zdyrski, C., Pawlak, A., Mochel, J. P., & Douglass, E. F. (2026). Gaps and paths forward in cancer pharmacology and translational research. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1779049

Vancouver

Hughes EA, Davenport LL, Zdyrski C, Pawlak A, Mochel JP, Douglass EF. Gaps and paths forward in cancer pharmacology and translational research. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1779049

BibTeX
@article{Hughes2026,
  author = {Hughes, Elizabeth A and Davenport, Lindsay L and Zdyrski, Christopher and Pawlak, Aleksandra and Mochel, Jonathan P and Douglass, Eugene F},
  title = {Gaps and paths forward in cancer pharmacology and translational research},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1779049}
}
Kostenlos starten →